| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure
|
Persico, M.
|
|
2016
|
48 |
S3 |
p. e233-
1 p.
|
article
|
| 2 |
Durable response in the markers of cholestasis through 18 months of open-label extension with obeticholic acid in primary biliary cholangitis
|
Trauner, M.
|
|
2016
|
48 |
S3 |
p. e236-
1 p.
|
article
|
| 3 |
Early changes in non-invasive assessment of liver fibrosis in hepatitis C virus-infected patients treated with DAAs: Preliminary reports
|
Iegri, C.
|
|
2016
|
48 |
S3 |
p. e238-e239
nvt p.
|
article
|
| 4 |
Editorial Board
|
|
|
2016
|
48 |
S3 |
p. i-
1 p.
|
article
|
| 5 |
Emerging increase in the prevalence and severity of nonalcoholic fatty liver disease: Epidemiological study from general Mediterranean population
|
Petta, S.
|
|
2016
|
48 |
S3 |
p. e238-
1 p.
|
article
|
| 6 |
Genotype 3 infection in DAA era: Preliminary reports of a real life northern Italy network for viral hepatitis
|
Pasulo, L.
|
|
2016
|
48 |
S3 |
p. e235-
1 p.
|
article
|
| 7 |
HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience
|
Shalaby, S.
|
|
2016
|
48 |
S3 |
p. e237-
1 p.
|
article
|
| 8 |
Hepatitis C patients with any degree of portal hypertension are at risk to develop serious adverse effect to direct-acting antiviral therapies
|
De Luca, L.
|
|
2016
|
48 |
S3 |
p. e234-
1 p.
|
article
|
| 9 |
Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study
|
Persico, M.
|
|
2016
|
48 |
S3 |
p. e234-
1 p.
|
article
|
| 10 |
Liver biopsy in Type 2 Diabetes Mellitus: Steatohepatitis represents the sole feature of liver damage
|
Masarone, M.
|
|
2016
|
48 |
S3 |
p. e237-
1 p.
|
article
|
| 11 |
New chitosan-coated liposomes for controlled release of active substances in HepG2 cells: Synthesis, biological characterization, cell viability and anti-inflammatory studies
|
Quagliariello, V.
|
|
2016
|
48 |
S3 |
p. e236-
1 p.
|
article
|
| 12 |
Real life of DAAs (direct antiviral agents) for HCV infection in Friuli Venezia Giulia: Who, why, what, how did we treat?
|
Masutti, F.
|
|
2016
|
48 |
S3 |
p. e238-
1 p.
|
article
|
| 13 |
TM6SF2 and MBOAT7 genotype to determine alcohol-related liver damage in patients with HCV chronic hepatitis
|
Degasperi, E.
|
|
2016
|
48 |
S3 |
p. e235-
1 p.
|
article
|
Journal description